-- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response will now exceed 22 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results